GNOM


Genomics & Biotechnology ETF

Reasons to Consider GNOM

High Growth Potential

Manufacturing genomic medicines is cumbersome, but new techniques using donated cells are more scalable and could slash production costs by 95%, potentially facilitating broader adoption.1

Structural Tailwinds

Recent regulatory approvals have helped genomic medicines gain momentum. Sales of genomic medicines are forecast to increase at a 47% compound annual growth rate from 2022-2028.2

Targeted Exposure

GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

1International Society for Cell and Gene Therapy, Feb 2019
2Evaluate Pharma, Nov 2023

Key Information As of 04/19/24

Inception Date 04/05/19
Total Expense Ratio 0.50%
Net Assets $88.26 million
NAV $9.68

ETF Summary

The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

ETF Objective

The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

Trading Details As of 04/19/24

Ticker GNOM
B3 Trading Code BGNO39
Bloomberg Index Ticker SOLGNOM
CUSIP 37954Y434
ISIN US37954Y4347
Primary Exchange Nasdaq
Shares Outstanding 9,120,000
Number of Holdings 0
30-Day Median Bid-Ask Spread 0.18%

Distributions As of 04/19/24

30-Day SEC Yield -0.21%
Distribution Frequency Semi-Annually

ETF Prices As of 04/19/24

NAV $9.68 Daily Change -$0.09 -0.92%
Market Price $9.68 Daily Change -$0.10 -1.02%

Performance History

Cumulative Returns (as of 03/28/24)
1 Month 6 Months YTD 12 Months 24 Months Since Inception Inception Date
Return GNOM -5.41% 11.93% -1.82% -7.57% -26.97% -25.53% 04/05/19
Returns (as of 04/18/24)
Return GNOM Return Index
Since Inception -35.95% -34.24%
12 Months -20.23% -19.12%
24 Months -23.39% -22.49%
Last 60 Trading Days -12.12% -11.93%
Last 75 Trading Days -15.54% -15.24%
Monthly Returns (through 04/18/24)
Return GNOM Return Index
Apr 2024 -13.98% -13.90%
Mar 2024 -5.41% -5.20%
Feb 2024 11.62% 11.55%
Jan 2024 -7.01% -6.90%
Dec 2023 11.12% 11.12%
Nov 2023 17.53% 17.71%
Oct 2023 -12.70% -12.66%
Sep 2023 -9.53% -9.44%
Aug 2023 -8.41% -8.28%
Jul 2023 1.22% 1.27%
Jun 2023 -0.83% -0.71%
May 2023 -0.40% 0.01%
Apr 2023 -0.32% -0.36%
Mar 2023 -2.40% -2.28%
Feb 2023 -7.07% -7.73%
Jan 2023 7.02% 7.13%
Dec 2022 -5.87% -5.89%
Nov 2022 2.37% 2.43%
Oct 2022 4.96% 5.00%
Sep 2022 -9.67% -9.59%
Aug 2022 -2.51% -2.52%
Jul 2022 16.09% 16.12%
Jun 2022 2.26% 2.22%
May 2022 -6.13% -5.96%
Apr 2022 -17.99% -18.04%

Total returns take into account management, administration and fees and other costs automatically deducted from the fund's assets. Before investing, you may read the prospectus in the “FEES AND EXPENSES” section for more details.

NAV & Index Chart

Top Holdings

Net Assets (%) Ticker Name Country SEDOL Market Price ($) Shares Held Market Value ($)
Holdings are subject to change. "Cash" denotes U.S. dollars.

Sector Breakdown As of 03/31/24

Sector Weight (%)
Health Care 93.1
Energy 6.9

Source: AltaVista Research, LLC

Country Breakdown As of 03/31/24

Country Weight (%)
United States 78.6
Italy 6.9
Switzerland 5.1
Netherlands 3.8
Germany 2.9
China 2.3
Japan 0.5

Source: AltaVista Research, LLC

ETF Characteristics As of 04/18/24

Return on Equity -16.20%
Weighted Avg. Market Cap 15,790 M
2023 2024
Price-to-earnings -13.72 -16.61
Price-to-book value 2.47 2.96

Source: AltaVista Research, LLC

ETF Risk Stats As of 03/31/24

Versus Beta
S&P 500 1.17
MSCI EAFE 1.05
MSCI Emg. Mkts 0.93
Standard Deviation 29.90%

Source: AltaVista Research, LLC

TERMS OF USE

Global X Brasil Gestora de Investimentos Ltda. (“Global X Brasil”) is an asset manager authorized by the Brazilian Securities and Exchange Commission (“CVM”), constituted in the form of CVM Resolution No. 21/2021. Investing involves risks. The material on this site is for informational purposes only and does not constitute investment advice, recommendation, offer or solicitation to buy or sell any securities, funds, or strategies to any person in any jurisdiction in which an offer, solicitation, purchase, or sale would be illegal under the securities laws of such jurisdiction. Opinions expressed here are subject to change without notice. Reliance upon the information contained in this material is at the sole discretion of the reader. No securities regulator has confirmed the accuracy of any information contained herein. Access to the information on this site or the use of the services or information provided herein is prohibited by any person or entity in any jurisdiction or country where such distribution or use is contrary to local law, rules, or regulation. Investment in index funds (ETFs) involves risks, including detachment from the benchmark index and related to the liquidity of shares in the secondary market. Investment funds managed by Global X Brasil use strategies that can result in significant equity losses for their quota holders. Global X Brasil, its partners and employees are exempt of responsibility for any damages resulting directly or indirectly from the use of the information contained on this website.

FOR EVALUATION OF THE PERFORMANCE OF AN INVESTMENT FUND, IT IS RECOMMENDED THE ANALYSIS OF AT LEAST 12 (TWELVE) MONTHS. INVESTMENT FUNDS DO NOT HAVE A GUARANTEE FROM THE ADMINISTRATOR, THE MANAGER, ANY INSURANCE MECHANISM OR CREDIT GUARANTEE FUND – FGC. INVESTMENTS IN FINANCIAL AND CAPITAL MARKETS ARE SUBJECT TO RISKS OF LOSS GREATER THAN THE TOTAL VALUE OF INVESTED CAPITAL. PAST PROFITABILITY DOES NOT REPRESENT A GUARANTEE OF FUTURE PROFITABILITY THE PROFITABILITY DISCLOSED IS NOT NET OF TAXES. READ THE PROSPECTUS, THE FORM OF COMPLEMENTARY INFORMATION, SHEET OF ESSENTIAL INFORMATION AND THE REGULATION BEFORE INVESTING. DESCRIPTION OF THE ANBIMA TYPE AVAILABLE IN THE FORM OF COMPLEMENTARY INFORMATION.

Back to Top